The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Quality of life in a multicenter phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Pablo Emilio Serrano Aybar
No relevant relationships to disclose
Joseph M. Herman
No relevant relationships to disclose
Mark Zalupski
No relevant relationships to disclose
Edward Jae-hoon Kim
No relevant relationships to disclose
Edgar Ben-Josef
No relevant relationships to disclose
Tanios S. Bekaii-Saab
No relevant relationships to disclose
Christopher Lee Wolfgang
No relevant relationships to disclose
Daniel A. Laheru
No relevant relationships to disclose
Malcolm J. Moore
No relevant relationships to disclose
Laura A. Dawson
No relevant relationships to disclose
Jolie Ringash
No relevant relationships to disclose
Alice Chia-chi Wei
No relevant relationships to disclose